NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

April 15, 2024

Study Completion Date

August 15, 2024

Conditions

CancerTumor, SolidMalignant NeoplasmMetastatic CancerAdvanced Solid TumorNon Small Cell Lung CancerMelanomaHead and Neck Squamous Cell CarcinomaLeiomyosarcomaLiposarcoma

Interventions

DRUG

OR2805

IgG1 monoclonal antibody that binds specifically to the CD163 protein.

DRUG

Cemiplimab

IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

DRUG

Docetaxel

An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.

Trial Locations (3)

78229

RECRUITING

NEXT Oncology, San Antonio

78758

RECRUITING

NEXT Austin, Austin

85258

RECRUITING

HonorHealth Research Institute, Scottsdale